Parallax Volatility Advisers
PTCT icon

Parallax Volatility Advisers’s PTC Therapeutics PTCT Stock Holding History

Parallax Volatility Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-25,000
Closed -$843K – 3351
2018
Q2 		$843K Buy
+25,000
New +$780K ﹤0.01% 1139
2018
Q1 		– Sell
-807,000
Closed -$13.5M – 3769
2017
Q4 		$13.5M Buy
+807,000
New +$13.7M 0.02% 333

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parallax Volatility Advisers's PTCT Position: Q1 2023 in Review

Parallax Volatility Advisers sold out of PTC Therapeutics (PTCT) in Q1 2023, closing a stake of 12,764 shares — an estimated $487K sold.

Parallax Volatility Advisers first reported a position in PTCT in Q2 2017 and held it in 5 quarters. The position peaked at $10.6M in Q4 2017. 202 funds tracked by Wall St. Rank hold PTCT as of Q1 2023.

  • Parallax Volatility Advisers reported no remaining PTC Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 12,764 PTC Therapeutics shares in Q1 2023, an estimated $487K.
  • Parallax Volatility Advisers first reported a position in PTC Therapeutics in Q2 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's PTC Therapeutics position peaked at $10.6M in Q4 2017.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2023.

Based on Parallax Volatility Advisers's 13F filing for Q1 2023, filed 15 May 2023.